Related references
Note: Only part of the references are listed.Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox
Greg Chittick et al.
ANTIVIRAL RESEARCH (2017)
Extended Human-to-Human Transmission during a Monkeypox Outbreak in the Democratic Republic of the Congo
Leisha Diane Nolen et al.
EMERGING INFECTIOUS DISEASES (2016)
Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE® smallpox vaccine
Jesse D. Troy et al.
VACCINE (2015)
Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease
Eric M. Mucker et al.
PLOS ONE (2015)
Discovery of forgotten variola specimens at the National Institutes of Health in the USA
Isao Arita
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2014)
Efficacy of Tecovirimat (ST-246) in Nonhuman Primates Infected with Variola Virus (Smallpox)
Eric M. Mucker et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Clinical development of Modified Vaccinia virus Ankara vaccines
Sarah C. Gilbert
VACCINE (2013)
Safety and Pharmacokinetics of the Anti-Orthopoxvirus Compound ST-246 following a Single Daily Oral Dose for 14 Days in Human Volunteers
Jarasvech Chinsangaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Lethal Monkeypox Virus Infection of CAST/EiJ Mice Is Associated with a Deficient Gamma Interferon Response
Patricia L. Earl et al.
JOURNAL OF VIROLOGY (2012)
Side-by-Side Comparison of Gene-Based Smallpox Vaccine with MVA in Nonhuman Primates
Joseph W. Golden et al.
PLOS ONE (2012)
Safety and Immunogenicity of LC16m8, an Attenuated Smallpox Vaccine in Vaccinia-Naive Adults
Jeffrey S. Kennedy et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Smallpox Vaccine Safety Is Dependent on T Cells and Not B Cells
Shari N. Gordon et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Control of vaccinia virus skin lesions by long-term-maintained IFN-γ+TNF-α+ effector/memory CD4+ lymphocytes in humans
Benedicte Puissant-Lubrano et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo
Anne W. Rimoin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification
Robert Jordan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246
John Huggins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Gender effects on humoral immune responses to smallpox vaccine
Richard B. Kennedy et al.
VACCINE (2009)
Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein
Hua-Poo Su et al.
VIROLOGY (2007)
Infectiousness of smallpox relative to disease age: estimates based on transmission network and incubation period
H. Nishiura et al.
EPIDEMIOLOGY AND INFECTION (2007)
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus
ZC Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge
S Lustig et al.
JOURNAL OF VIROLOGY (2005)
The detection of monkeypox in humans in the Western Hemisphere
KD Reed et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions
C Fogg et al.
JOURNAL OF VIROLOGY (2004)
Share Paper
